its experimental therapy for congenital adrenal hyperplasia (CAH). CAH, a group of genetic disorders affecting adrenal glands, is characterized by excessive levels of androstenedione (A4), a ...
While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, the U.S. FDA approved Crenessity (crinecerfont) from ...
No consistent clinically important trends were observed across key safety parameters, including clinical safety laboratory values, physical examination ... is currently in development for congenital ...
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, announced positive topline results from an open-label, phase 2 congenital adrenal hyperplasia (CAH ... clinical safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback